TY - JOUR
T1 - Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort
T2 - Strong correlation with BCL2 translocation
AU - Schejbel, Lone
AU - Breinholt, Marie Fredslund
AU - Gang, Anne Ortved
AU - Nielsen, Torsten Holm
AU - Pedersen, Lars Møller
AU - Høgdall, Estrid
AU - Nørgaard, Peter
N1 - © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2022/8
Y1 - 2022/8
N2 - Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.
AB - Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.
U2 - 10.1002/jha2.489
DO - 10.1002/jha2.489
M3 - Journal article
C2 - 36051027
SN - 2688-6146
VL - 3
SP - 936
EP - 939
JO - EJHaem
JF - EJHaem
IS - 3
ER -